SIRT1 and melanoma: With the accumulated evidence about SIRT1's function in cancer, EX-527 and other SIRT inhibitors have been studied as potential therapies in multiple cancer cells, including melanoma 35, hepatocellular carcinoma 36, chronic lymphocytic leukemia 37, and lung cancer 38.